-
Uncategorized2 months ago
Trevi raises $150M; Spain and Boston set up biotech fund
Plus, news about UK clinical studies and Kura Oncology: Trevi Therapeutics to sell $150M in shares: The biotech plans to float more than 11.5 million shares...
-
Uncategorized2 months agoLilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell...
-
Uncategorized2 months agoSTAT+: FDA eyes expanding testosterone therapy for libido
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hellooooo, friends. Psychedelics and testosterone...
-
Uncategorized2 months ago
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison...
-
Uncategorized2 months ago
Biovac gets $108M backing for vaccine factory in South Africa
Biovac’s new vaccine factory in Cape Town, which is expected to make up to 40 million vaccines per year, has secured financing from the European Investment...
-
Uncategorized2 months ago
TRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACR
Minimal residual disease (MRD) continues to be a central focus at the AACR meeting. The small numbers of cancer cells that remain in the body after...
-
Uncategorized2 months ago
UPDATE: Kailera breaks biotech IPO record with $625M debut
Obesity-focused Kailera Therapeutics debuted on the Nasdaq Friday after raising a record $625 million, beating Moderna’s $600 million from 2018.
-
Uncategorized2 months ago
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
-
Uncategorized2 months ago
Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the...
-
Uncategorized2 months ago
Novo may have muscle advantage over Lilly in weight-loss race: preprint
More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
